Insulin Resistance – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Insulin Resistance Market Outlook

Thelansis’s “Insulin Resistance Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Insulin Resistance treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Insulin Resistance Overview

Insulin resistance is when the body exhibits an insufficient biological response to normal insulin levels. In essence, it can affect various insulin-related functions in different bodily tissues. However, in clinical practice, insulin resistance is commonly understood as a state in which a given amount of insulin results in an inadequate glucose response. The origins of insulin resistance can be attributed to genetic and acquired factors. Genetic factors include mutations in insulin receptors, glucose transporters, and signaling proteins, although the precise causes of common forms remain largely unknown. Acquired factors encompass physical inactivity, dietary habits, medications, high blood sugar levels (known as glucose toxicity), elevated levels of free fatty acids, and the natural aging process. The underlying causes of insulin resistance can be classified based on whether their primary impact occurs before, at, or after the insulin receptor. Pre-receptor causes include abnormal insulin (due to mutations) and anti-insulin antibodies. Receptor-related causes include reduced receptors, failure to activate tyrosine kinase, diminished insulin binding, insulin receptor mutations, and antibodies that block insulin receptors. Post-receptor causes encompass defective signal transduction and, in theory, mutations in the GLUT4 gene, although these mutations are rare. Symptoms of insulin resistance encompass increased thirst, frequent urination, heightened appetite, blurred vision, headaches, vaginal and skin infections, and slow wound healing. Factors associated with a higher likelihood of developing insulin resistance include a strong family history of diabetes, gestational diabetes, and polycystic ovary syndrome. Impaired glucose metabolism, defined as fasting glucose levels between 110 and 125 mg per dL (6.1 and 7.1 mmol per L) or impaired glucose tolerance with a two-hour post–75-g glucose load level between 140 and 199 mg per dL (7.8 and 11.1 mmol per L), also contribute to this condition. Additionally, obesity, defined as a body mass index of 30 kg per m2 or higher, and an increased waist-to-hip ratio (1.0 in men and 0.8 in women) are associated with insulin resistance.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Insulin Resistance – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment